Home LiteratureArticle Details
PMID: 9414264 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Multiple myeloma: increasing evidence for a multistep transformation process.

Blood ·Vol. 91 ·No. 1 ·1998-01-01 ·Pages 3-21

Hallek M, Bergsagel PL, Anderson KC

Abstract

暂无摘要

MeSH Terms
Antigens, Surface/physiology Apoptosis/genetics Bone Marrow/pathology Cell Adhesion Molecules/physiology Cell Cycle Cell Transformation, Neoplastic DNA, Neoplasm/genetics Drug Resistance, Multiple/genetics Drug Resistance, Neoplasm/genetics Genes, Retinoblastoma Genes, Switch Growth Substances/physiology Humans Immunoglobulin Heavy Chains/genetics Interleukin-6/antagonists & inhibitors,physiology Lymph Nodes/pathology Multiple Myeloma/etiology,genetics,immunology,pathology,therapy Oncogenes Plasma Cells/pathology Signal Transduction Translocation, Genetic
Chemicals
Antigens, Surface Cell Adhesion Molecules DNA, Neoplasm Growth Substances Immunoglobulin Heavy Chains Interleukin-6
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Hallek M
Medizinische Klinik, Klinikum Innenstadt, and Genzentrum, Universität M-unchen, M-unchen, Germany.
Bergsagel P L
Anderson K C
References (305)
305 references, click to expand
  1. Non-random chromosomal aberrations associated with multiple myeloma.
    Hematol Oncol. 1984 Oct-Dec;2(4):307-17 PMID: 6335483
  2. Phenotypic difference of normal plasma cells from mature myeloma cells.
    Blood. 1993 May 15;81(10):2658-63 PMID: 8490175
  3. Hemopoietic cell growth factors and their receptors.
    Annu Rev Biochem. 1989;58:45-77 PMID: 2549855
  4. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells.
    Blood. 1992 Jan 15;79(2):495-502 PMID: 1730093
  5. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.
    Cell. 1992 Aug 7;70(3):431-42 PMID: 1322798
  6. Multiple cytokines inhibit interleukin-6-dependent murine hybridoma/plasmacytoma proliferation.
    Cell Immunol. 1996 Feb 25;168(1):117-21 PMID: 8599834
  7. Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations.
    Cancer Res. 1995 Nov 1;55(21):5012-8 PMID: 7585544
  8. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells.
    Blood. 1995 Jul 1;86(1):381-9 PMID: 7540887
  9. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.
    Exp Hematol. 1997 Dec;25(13):1367-77 PMID: 9406996
  10. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.
    Blood. 1995 Dec 1;86(11):4250-6 PMID: 7492784
  11. Cytogenetic study in multiple myeloma.
    Cancer Genet Cytogenet. 1984 Jul;12(3):247-53 PMID: 6722764
  12. STATs: signal transducers and activators of transcription.
    Cell. 1996 Feb 9;84(3):331-4 PMID: 8608586
  13. Karyotype in multiple myeloma and plasma cell leukaemia.
    Eur J Cancer. 1993;29A(9):1269-73 PMID: 8343266
  14. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.
    N Engl J Med. 1990 May 17;322(20):1430-4 PMID: 2184356
  15. Nuclear signaling by interleukin-6.
    Curr Opin Immunol. 1993 Feb;5(1):124-8 PMID: 8452668
  16. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.
    Science. 1994 Jan 7;263(5143):89-92 PMID: 8272872
  17. Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption.
    Blood. 1990 Feb 1;75(3):715-20 PMID: 2297574
  18. Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas.
    Philos Trans R Soc Lond B Biol Sci. 1994 Aug 30;345(1313):281-7 PMID: 7531345
  19. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF).
    FASEB J. 1990 Aug;4(11):2860-7 PMID: 2199284
  20. Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth.
    Leuk Res. 1996 Apr;20(4):303-7 PMID: 8642841
  21. Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements.
    Int J Cancer. 1995 Dec 11;63(6):823-30 PMID: 8847141
  22. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells.
    Blood. 1990 Dec 15;76(12):2599-605 PMID: 2265252
  23. The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases.
    Leuk Lymphoma. 1995 Aug;18(5-6):497-503 PMID: 8528059
  24. Insulin-like growth factor-1 induces rapid tyrosine phosphorylation of the vav proto-oncogene product.
    Exp Hematol. 1996 Apr;24(5):622-7 PMID: 8605967
  25. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma.
    EMBO J. 1995 Dec 15;14(24):6209-17 PMID: 8557040
  26. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line.
    Eur J Haematol. 1994 Jul;53(1):31-7 PMID: 8062895
  27. Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial multiple myeloma pedigrees.
    Leukemia. 1993 Jul;7(7):986-91 PMID: 8321049
  28. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.
    Blood. 1993 May 15;81(10):2708-13 PMID: 8490179
  29. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
    Nat Genet. 1996 Jun;13(2):233-7 PMID: 8640234
  30. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
    EMBO J. 1994 Feb 15;13(4):764-73 PMID: 8112292
  31. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.
    Blood. 1996 Mar 1;87(5):1928-38 PMID: 8634441
  32. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells.
    Br J Haematol. 1995 Jul;90(3):693-6 PMID: 7647011
  33. Does the product of the RB-1 locus have a cell cycle regulatory function?
    Princess Takamatsu Symp. 1989;20:187-90 PMID: 2535107
  34. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group.
    Br J Haematol. 1996 Feb;92(2):370-4 PMID: 8603002
  35. Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25.
    Genomics. 1996 Oct 15;37(2):229-33 PMID: 8921401
  36. Involvement of Janus kinases, p52shc, Raf-1, and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth-responsive B cell line.
    J Immunol. 1994 Nov 15;153(10):4436-47 PMID: 7963520
  37. Bcl-2 protein expression is not related to short survival in multiple myeloma.
    Leukemia. 1995 Jul;9(7):1282-4 PMID: 7630204
  38. Interleukin-6 inhibits apoptosis of malignant plasma cells.
    Cell Immunol. 1995 May;162(2):248-55 PMID: 7743552
  39. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL.
    Cancer Res. 1995 Jun 1;55(11):2262-5 PMID: 7757973
  40. Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases.
    Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):8869-73 PMID: 1409579
  41. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling.
    Nature. 1993 May 6;363(6424):85-8 PMID: 8479541
  42. Shc, Grb2, Sos1, and a 150-kilodalton tyrosine-phosphorylated protein form complexes with Fms in hematopoietic cells.
    Mol Cell Biol. 1994 Sep;14(9):5682-91 PMID: 7520523
  43. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.
    Science. 1994 Jun 3;264(5164):1415-21 PMID: 8197455
  44. Amplification of the c-myc oncogene in human plasma-cell leukemia.
    Int J Cancer. 1985 Sep 15;36(3):367-71 PMID: 2863225
  45. Frequent hypermethylation of p16 and p15 genes in multiple myeloma.
    Blood. 1997 Apr 1;89(7):2500-6 PMID: 9116295
  46. Correlation between in vitro and in vivo sensitivity to human leucocyte interferon in patients with multiple myeloma.
    Scand J Haematol. 1985 Nov;35(5):543-9 PMID: 4089532
  47. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.
    Leuk Lymphoma. 1994 Jan;12(3-4):265-71 PMID: 8167557
  48. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
    Nat Genet. 1997 Jul;16(3):260-4 PMID: 9207791
  49. Differential shedding of the two subunits of the interleukin-6 receptor.
    FEBS Lett. 1993 Oct 11;332(1-2):174-8 PMID: 8405437
  50. Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein.
    Blood. 1993 Oct 15;82(8):2296-303 PMID: 8400282
  51. Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation.
    EMBO J. 1994 Mar 15;13(6):1357-67 PMID: 7511100
  52. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma.
    Leukemia. 1995 Dec;9(12):2109-14 PMID: 8609724
  53. Signal transduction via the MAP kinases: proceed at your own RSK.
    Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):5889-92 PMID: 8392180
  54. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function.
    Science. 1997 Jan 24;275(5299):540-3 PMID: 8999800
  55. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1.
    Blood. 1996 Jul 1;88(1):268-76 PMID: 8704183
  56. Mutations of the p53 gene in human myeloma cell lines.
    Oncogene. 1992 May;7(5):1015-8 PMID: 1373872
  57. Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells.
    J Immunol. 1995 Apr 15;154(8):4091-8 PMID: 7706747
  58. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells.
    Nature. 1989 May 4;339(6219):27-30 PMID: 2469962
  59. Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen.
    Blood. 1994 Nov 1;84(9):3134-41 PMID: 7524766
  60. Cytokine signal transduction.
    Cell. 1994 Jan 28;76(2):253-62 PMID: 8293462
  61. Kaposi's sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
    Semin Diagn Pathol. 1997 Feb;14(1):54-66 PMID: 9044510
  62. Molecular thanatopsis: a discourse on the BCL2 family and cell death.
    Blood. 1996 Jul 15;88(2):386-401 PMID: 8695785
  63. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2.
    Science. 1993 May 28;260(5112):1338-43 PMID: 8493579
  64. Tumor suppressor genes.
    Science. 1991 Nov 22;254(5035):1138-46 PMID: 1659741
  65. Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes.
    Blood. 1991 Jul 15;78(2):493-8 PMID: 2070085
  66. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma.
    Br J Haematol. 1996 May;93(2):398-400 PMID: 8639436
  67. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.
    Blood. 1995 May 1;85(9):2490-7 PMID: 7537117
  68. Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma.
    Blood. 1992 Apr 1;79(7):1775-80 PMID: 1558971
  69. Combining two mutations of human interleukin-6 that affect gp130 activation results in a potent interleukin-6 receptor antagonist on human myeloma cells.
    J Biol Chem. 1995 Apr 7;270(14):8158-63 PMID: 7713920
  70. Interleukin-6 in clinical medicine.
    Ann Hematol. 1991 Jun;62(6):203-10 PMID: 1854882
  71. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein.
    Blood. 1996 Sep 15;88(6):2219-27 PMID: 8822942
  72. Regulators and effectors of ras proteins.
    Annu Rev Cell Biol. 1991;7:601-32 PMID: 1667084
  73. Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies.
    Mol Med Today. 1996 Oct;2(10):425-31 PMID: 8897437
  74. The development of a model for the homing of multiple myeloma cells to human bone marrow.
    Blood. 1997 Jul 15;90(2):754-65 PMID: 9226176
  75. Signal transduction by receptors with tyrosine kinase activity.
    Cell. 1990 Apr 20;61(2):203-12 PMID: 2158859
  76. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.
    Blood. 1997 Jan 1;89(1):227-34 PMID: 8978296
  77. Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma.
    Br J Haematol. 1997 Jan;96(1):98-102 PMID: 9012694
  78. Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3' of the myc gene, is rearranged in multiple myelomas.
    Cancer Res. 1990 Oct 15;50(20):6478-82 PMID: 2208106
  79. Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active Ras.GTP complex in rat pheochromocytoma PC12 cells.
    J Biol Chem. 1992 Sep 25;267(27):19448-54 PMID: 1527065
  80. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.
    Blood. 1989 Feb;73(2):517-26 PMID: 2783861
  81. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines.
    J Biol Chem. 1996 Oct 4;271(40):24655-61 PMID: 8798732
  82. Functional and biochemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells.
    EMBO J. 1994 Apr 1;13(7):1574-84 PMID: 8156996
  83. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components.
    Science. 1994 Jan 7;263(5143):92-5 PMID: 8272873
  84. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.
    J Immunol. 1991 Dec 15;147(12):4402-7 PMID: 1753108
  85. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Blood. 1996 Jan 1;87(1):265-72 PMID: 8547651
  86. Expression of myc-family genes in established human multiple myeloma cell lines: L-myc but not c-myc gene expression in the U-266 myeloma cell line.
    Int J Cancer. 1992 Apr 22;51(1):116-23 PMID: 1563831
  87. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.
    Cancer Res. 1993 Feb 15;53(4):851-6 PMID: 8428365
  88. Identification and characterization of a new mammalian mitogen-activated protein kinase kinase, MKK2.
    Mol Cell Biol. 1993 Aug;13(8):4539-48 PMID: 8393135
  89. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells.
    EMBO J. 1989 Aug;8(8):2283-90 PMID: 2477241
  90. A common FGFR3 gene mutation is present in achondroplasia but not in hypochondroplasia.
    Am J Med Genet. 1995 Jan 2;55(1):127-33 PMID: 7702086
  91. Cytokine network in human multiple myeloma.
    Hematol Oncol Clin North Am. 1992 Apr;6(2):273-84 PMID: 1582974
  92. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor.
    Cell. 1993 May 7;73(3):611-20 PMID: 8490966
  93. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?
    Acta Haematol. 1997;97(1-2):40-52 PMID: 8980609
  94. Inhibitors of Ras farnesyltransferases.
    Trends Biochem Sci. 1993 Sep;18(9):349-53 PMID: 8236454
  95. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.
    Eur J Immunol. 1993 Apr;23(4):820-4 PMID: 8458373
  96. In vitro growth of human multiple myeloma: implications for biology and therapy.
    Hematol Oncol Clin North Am. 1992 Apr;6(2):257-71 PMID: 1582973
  97. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation.
    J Biol Chem. 1996 May 31;271(22):12999-3007 PMID: 8662795
  98. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms.
    Blood. 1990 Mar 1;75(5):1114-8 PMID: 2306518
  99. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1.
    Nature. 1993 May 6;363(6424):83-5 PMID: 8479540
  100. CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity.
    Leuk Lymphoma. 1996 Mar;21(1-2):1-8 PMID: 8907262
  101. Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes.
    Science. 1989 Feb 3;243(4891):660-3 PMID: 2536954
  102. Acute phase proteins and prognosis in multiple myeloma.
    Br J Haematol. 1993 Apr;83(4):595-601 PMID: 7686034
  103. Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro.
    Blood. 1994 Nov 1;84(9):3026-33 PMID: 7524765
  104. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules.
    Hematol Oncol Clin North Am. 1992 Apr;6(2):297-322 PMID: 1533857
  105. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
    Leukemia. 1994 May;8(5):758-67 PMID: 8182933
  106. Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response.
    Gene Ther. 1997 Jul;4(7):726-35 PMID: 9282174
  107. Erks: their fifteen minutes has arrived.
    Cell Growth Differ. 1992 Feb;3(2):135-42 PMID: 1504018
  108. Differential sensitivity of human myeloma cell lines and normal bone marrow colony forming cells to a recombinant diphtheria toxin-interleukin 6 fusion protein.
    Br J Haematol. 1993 Sep;85(1):25-36 PMID: 8251407
  109. Mitogen-activated protein kinases and ribosomal S6 protein kinases are involved in signaling pathways shared by interleukin-11, interleukin-6, leukemia inhibitory factor, and oncostatin M in mouse 3T3-L1 cells.
    J Biol Chem. 1994 Feb 4;269(5):3731-8 PMID: 7508917
  110. A new cytokine receptor superfamily.
    Trends Biochem Sci. 1990 Jul;15(7):265-70 PMID: 2166365
  111. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.
    Ann Hematol. 1991 Feb-Mar;62(2-3):54-8 PMID: 2031968
  112. Louvain rat immunocytomas.
    Adv Cancer Res. 1988;50:279-310 PMID: 3287846
  113. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6.
    Science. 1994 Apr 1;264(5155):95-8 PMID: 8140422
  114. Retinoic acid modulates the in vivo and in vitro growth of IL-6 autocrine human myeloma cell lines via induction of apoptosis.
    Clin Exp Immunol. 1996 Apr;104(1):167-72 PMID: 8603522
  115. Cytokine receptors and signal transduction.
    Annu Rev Immunol. 1992;10:295-331 PMID: 1590989
  116. The biology of interleukin-6.
    Blood. 1989 Jul;74(1):1-10 PMID: 2473791
  117. The role of p53, bcl-2 and bax network in dexamethasone induced apoptosis in multiple myeloma cell lines.
    Int J Oncol. 1996 Apr;8(4):719-26 PMID: 21544419
  118. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor.
    Nature. 1986 Jan 30-Feb 5;319(6052):415-8 PMID: 3484805
  119. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.
    Nature. 1994 Sep 15;371(6494):252-4 PMID: 8078586
  120. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells.
    J Exp Med. 1994 Dec 1;180(6):2395-400 PMID: 7964514
  121. Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies.
    Br J Haematol. 1994 Aug;87(4):735-42 PMID: 7986715
  122. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes.
    Annu Rev Immunol. 1992;10:785-807 PMID: 1591003
  123. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.
    J Exp Med. 1994 Apr 1;179(4):1337-42 PMID: 8145045
  124. Cytokine signal transduction and the JAK family of protein tyrosine kinases.
    Bioessays. 1994 May;16(5):313-20 PMID: 8024540
  125. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells.
    Cancer Res. 1996 Mar 15;56(6):1451-6 PMID: 8640839
  126. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients.
    Science. 1997 Jun 20;276(5320):1851-4 PMID: 9188529
  127. Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites.
    Blood. 1996 Jan 1;87(1):314-23 PMID: 8547658
  128. Plasma cell karyotype in multiple myeloma.
    Blood. 1988 Feb;71(2):453-6 PMID: 3337907
  129. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II.
    EMBO J. 1994 Sep 1;13(17):4070-9 PMID: 8076602
  130. Oncostatin M induces tyrosine phosphorylation in endothelial cells and activation of p62yes tyrosine kinase.
    J Immunol. 1992 Sep 1;149(5):1676-82 PMID: 1324279
  131. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6.
    Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2207-11 PMID: 8384717
  132. Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment--impact on treatment of myeloproliferative disorders.
    Leuk Lymphoma. 1996 Sep;22 Suppl 1:129-34 PMID: 8951783
  133. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop.
    Blood. 1996 Nov 15;88(10):3972-86 PMID: 8916964
  134. Purification and characterization of the Fas-ligand that induces apoptosis.
    J Exp Med. 1994 Mar 1;179(3):873-9 PMID: 7509364
  135. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis.
    EMBO J. 1996 Jul 15;15(14):3693-701 PMID: 8758936
  136. Multiple hemopoietins, with the exception of interleukin-4, induce modification of Shc and mSos1, but not their translocation.
    J Biol Chem. 1994 Aug 19;269(33):21165-76 PMID: 8063737
  137. A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene.
    Blood. 1994 Aug 15;84(4):1226-31 PMID: 8049438
  138. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines.
    Leuk Lymphoma. 1995 May;17(5-6):485-94 PMID: 7549842
  139. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias.
    Cancer. 1992 Mar 15;69(6):1373-6 PMID: 1540875
  140. Interleukin-6 prevents dexamethasone-induced myeloma cell death.
    Blood. 1994 Nov 1;84(9):3063-70 PMID: 7949178
  141. Correlations between karyotype and cytologic findings in multiple myeloma.
    Leukemia. 1995 Dec;9(12):2119-22 PMID: 8609726
  142. Interferon-alpha down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266.
    Biochem J. 1995 Jul 1;309 ( Pt 1):175-80 PMID: 7619053
  143. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation.
    J Biol Chem. 1996 May 31;271(22):12991-8 PMID: 8662591
  144. Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha.
    Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7836-9 PMID: 1502203
  145. Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells.
    Blood. 1993 Oct 15;82(8):2371-8 PMID: 8400288
  146. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation.
    Immunol Today. 1992 Nov;13(11):431-3 PMID: 1282319
  147. Bcl-2 initiates a new category of oncogenes: regulators of cell death.
    Blood. 1992 Aug 15;80(4):879-86 PMID: 1498330
  148. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1).
    Hum Mol Genet. 1996 Apr;5(4):509-12 PMID: 8845844
  149. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.
    J Clin Invest. 1991 Jul;88(1):62-6 PMID: 2056131
  150. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
    J Clin Invest. 1989 Dec;84(6):2008-11 PMID: 2592570
  151. cPLA2 is phosphorylated and activated by MAP kinase.
    Cell. 1993 Jan 29;72(2):269-78 PMID: 8381049
  152. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation.
    Blood. 1989 Feb 15;73(3):747-52 PMID: 2563664
  153. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction.
    Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7840-3 PMID: 1502204
  154. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes.
    Am J Pathol. 1996 Jul;149(1):153-61 PMID: 8686739
  155. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance.
    Blood. 1995 Nov 15;86(10):3915-21 PMID: 7579361
  156. Regulators of cell death.
    Trends Genet. 1995 Mar;11(3):101-5 PMID: 7732571
  157. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells.
    Science. 1986 Apr 4;232(4746):61-5 PMID: 2420009
  158. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements.
    Blood. 1997 Mar 1;89(5):1824-33 PMID: 9057669
  159. Hepatocyte growth factor and its receptor c-met in multiple myeloma.
    Blood. 1996 Nov 15;88(10):3998-4004 PMID: 8916966
  160. ras genes.
    Annu Rev Biochem. 1987;56:779-827 PMID: 3304147
  161. Elevated c-myc messenger RNA in multiple myeloma cell lines.
    Dis Markers. 1990 May-Jun;8(3):117-24 PMID: 1980237
  162. Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors.
    J Biol Chem. 1994 Apr 15;269(15):11648-55 PMID: 7512571
  163. Deletion of the retinoblastoma gene in multiple myeloma.
    Leukemia. 1994 Aug;8(8):1280-4 PMID: 8057662
  164. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells.
    Clin Cancer Res. 1997 Jun;3(6):1017-22 PMID: 9815779
  165. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells.
    Blood. 1997 Sep 1;90(5):1982-92 PMID: 9292533
  166. A high frequency of N-RAS oncogene mutations in multiple myeloma.
    Int J Hematol. 1992 Oct;56(2):119-27 PMID: 1421173
  167. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
    Cancer Res. 1996 Sep 15;56(18):4213-8 PMID: 8797594
  168. High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells.
    Br J Haematol. 1995 Nov;91(3):664-7 PMID: 8555072
  169. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
    Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13931-6 PMID: 8943038
  170. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.
    Cancer Res. 1995 Aug 15;55(16):3640-6 PMID: 7627974
  171. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.
    Blood. 1991 Sep 1;78(5):1198-204 PMID: 1715218
  172. How receptor tyrosine kinases activate Ras.
    Trends Biochem Sci. 1993 Aug;18(8):273-5 PMID: 8236435
  173. Tumor growth stimulation in vitro by interferons.
    Eur J Cancer Clin Oncol. 1983 Nov;19(11):1625-32 PMID: 6580172
  174. Generation of a fusion partner to sample the repertoire of splenic B cells destined for apoptosis.
    Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5548-51 PMID: 8202525
  175. gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro.
    Blood. 1993 Jun 1;81(11):3076-82 PMID: 8499642
  176. The Fas death factor.
    Science. 1995 Mar 10;267(5203):1449-56 PMID: 7533326
  177. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD.
    Blood. 1989 Aug 15;74(3):913-7 PMID: 2568864
  178. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation.
    Oncogene. 1992 Jul;7(7):1401-6 PMID: 1535701
  179. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.
    J Biol Chem. 1994 Feb 18;269(7):5016-21 PMID: 7508932
  180. The cellular effects of E2F overexpression.
    Curr Top Microbiol Immunol. 1996;208:79-93 PMID: 8575214
  181. Interleukin-6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP-1.
    Eur J Immunol. 1996 Feb;26(2):379-84 PMID: 8617307
  182. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.
    J Clin Invest. 1994 Dec;94(6):2317-25 PMID: 7989587
  183. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases.
    Nature. 1992 Dec 17;360(6405):689-92 PMID: 1465135
  184. 'Role of bone marrow stromal cells in the growth of human multiple myeloma.
    Blood. 1991 Jun 15;77(12):2688-93 PMID: 1675130
  185. Frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukemia.
    Blood. 1996 Sep 1;88(5):1568-75 PMID: 8781411
  186. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.
    Nat Genet. 1995 Dec;11(4):462-4 PMID: 7493034
  187. IL-6 receptor and mechanism of signal transduction.
    Int J Immunopharmacol. 1992 Apr;14(3):431-8 PMID: 1618596
  188. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells.
    Eur Cytokine Netw. 1995 May-Jun;6(3):135-43 PMID: 8589270
  189. RAS gene mutations in multiple myeloma and related monoclonal gammopathies.
    Kobe J Med Sci. 1991 Feb;37(1):35-45 PMID: 1921261
  190. Image analysis in multiple myeloma at diagnosis. Correlation with cytogenetic study.
    Cancer Genet Cytogenet. 1994 Jun;74(2):115-9 PMID: 8019954
  191. Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia.
    Clin Cancer Res. 1997 Nov;3(11):2173-9 PMID: 9815612
  192. The function of GRB2 in linking the insulin receptor to Ras signaling pathways.
    Science. 1993 Jun 25;260(5116):1953-5 PMID: 8316835
  193. The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system.
    Scand J Haematol. 1985 Aug;35(2):178-85 PMID: 4048864
  194. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.
    J Immunol. 1997 Sep 1;159(5):2212-21 PMID: 9278309
  195. Cytokine receptors and signal transduction.
    FASEB J. 1992 Dec;6(15):3387-96 PMID: 1334470
  196. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor.
    Science. 1992 Aug 7;257(5071):809-13 PMID: 1496401
  197. Biological aspects of multiple myeloma.
    Baillieres Clin Haematol. 1995 Dec;8(4):721-34 PMID: 8845569
  198. Rare occurrence of P53 gene mutations in multiple myeloma.
    Br J Haematol. 1992 Jul;81(3):440-3 PMID: 1390218
  199. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase.
    Science. 1993 Jun 18;260(5115):1808-10 PMID: 8511589
  200. Proteins of the Myc network: essential regulators of cell growth and differentiation.
    Adv Cancer Res. 1996;68:109-82 PMID: 8712067
  201. p53 and RAS gene mutations in multiple myeloma.
    Oncogene. 1992 Dec;7(12):2539-43 PMID: 1461658
  202. N-ras and p53 gene mutations are very rare events in multiple myeloma.
    Int J Hematol. 1995 Aug;62(2):91-7 PMID: 8590778
  203. B cell antigen receptor stimulation induces formation of a Shc-Grb2 complex containing multiple tyrosine-phosphorylated proteins.
    J Biol Chem. 1994 Aug 12;269(32):20209-12 PMID: 8051109
  204. Interleukin-6 signals activating junB and TIS11 gene transcription in a B-cell hybridoma.
    Mol Cell Biol. 1991 Mar;11(3):1409-18 PMID: 1705005
  205. Phosphorylation of the TAL1 oncoprotein by the extracellular-signal-regulated protein kinase ERK1.
    Mol Cell Biol. 1993 Feb;13(2):801-8 PMID: 8423803
  206. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.
    Blood. 1996 Feb 1;87(3):1104-12 PMID: 8562936
  207. Interleukin-6 in human multiple myeloma.
    Blood. 1995 Feb 15;85(4):863-72 PMID: 7849308
  208. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone.
    Blood. 1996 Dec 15;88(12):4659-66 PMID: 8977259
  209. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.
    Blood. 1996 Jul 15;88(2):674-81 PMID: 8695815
  210. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element.
    Cell. 1989 Sep 22;58(6):1085-95 PMID: 2673542
  211. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.
    Blood. 1994 Jun 15;83(12):3654-63 PMID: 8204890
  212. Recent progress in multiple myeloma.
    Hematol Oncol. 1994 May-Jun;12(3):111-23 PMID: 7525447
  213. CD40 ligand triggered interleukin-6 secretion in multiple myeloma.
    Blood. 1995 Apr 1;85(7):1903-12 PMID: 7535594
  214. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules.
    J Immunol. 1992 Nov 1;149(9):2841-50 PMID: 1383329
  215. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein.
    Science. 1992 Dec 11;258(5089):1808-12 PMID: 1281555
  216. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130.
    Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2285-9 PMID: 8134389
  217. The human hematopoietic colony-stimulating factors.
    Science. 1987 Jun 5;236(4806):1229-37 PMID: 3296190
  218. Ras oncogene mutation in multiple myeloma.
    J Exp Med. 1989 Nov 1;170(5):1715-25 PMID: 2681517
  219. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med. 1996 Jan 15;124(2):212-22 PMID: 8533996
  220. Tumor suppressor genes.
    Neuron. 1993 Aug;11(2):191-6 PMID: 8352939
  221. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells.
    Blood. 1997 Jul 1;90(1):279-89 PMID: 9207463
  222. Signaling by the cytokine receptor superfamily: JAKs and STATs.
    Trends Biochem Sci. 1994 May;19(5):222-7 PMID: 8048164
  223. Proto-oncogene analysis in multiple myeloma.
    Am J Pathol. 1992 Oct;141(4):949-53 PMID: 1415486
  224. Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance.
    Blood. 1996 Jan 15;87(2):746-55 PMID: 8555499
  225. Tyrosine phosphorylation of the vav proto-oncogene product in activated B cells.
    Science. 1992 May 22;256(5060):1196-9 PMID: 1375396
  226. Genetic determinants of p53-induced apoptosis and growth arrest.
    Genes Dev. 1996 Aug 1;10(15):1945-52 PMID: 8756351
  227. Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis.
    Blood. 1991 Jul 1;78(1):180-91 PMID: 2070052
  228. Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells.
    J Immunol. 1989 Dec 1;143(11):3543-7 PMID: 2685119
  229. Fas and Fas ligand: a death factor and its receptor.
    Adv Immunol. 1994;57:129-44 PMID: 7532907
  230. A common FGFR3 gene mutation in hypochondroplasia.
    Hum Mol Genet. 1995 Nov;4(11):2097-101 PMID: 8589686
  231. Recombinant interferon-gamma inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro.
    Eur J Haematol. 1991 Apr;46(4):231-9 PMID: 1826658
  232. Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells.
    J Exp Med. 1995 Dec 1;182(6):1801-6 PMID: 7500025
  233. Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma.
    Blood. 1988 Jan;71(1):30-5 PMID: 3275475
  234. The role of CD40 in the regulation of humoral and cell-mediated immunity.
    Immunol Today. 1994 Sep;15(9):406-11 PMID: 7524518
  235. The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus.
    Eur J Clin Invest. 1996 Jan;26(1):1-12 PMID: 8682149
  236. Biological and clinical aspects of interleukin 6.
    Immunol Today. 1990 Dec;11(12):443-9 PMID: 2127356
  237. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction.
    Blood. 1994 Nov 1;84(9):3040-6 PMID: 7949175
  238. C-kit ligand (SCF) in human multiple myeloma cells.
    Leuk Lymphoma. 1996 Feb;20(5-6):457-64 PMID: 8833403
  239. The effector interactions of p21ras.
    Trends Biochem Sci. 1993 Jul;18(7):250-4 PMID: 8212134
  240. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
    Bone Marrow Transplant. 1997 Mar;19(6):553-6 PMID: 9085734
  241. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells.
    Blood. 1996 Jun 1;87(11):4510-9 PMID: 8639818
  242. Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry.
    Am J Clin Pathol. 1995 Jun;103(6):756-60 PMID: 7540362
  243. The CD40 antigen and its ligand.
    Annu Rev Immunol. 1994;12:881-922 PMID: 7516669
  244. Interferon-beta interrupts interleukin-6-dependent signaling events in myeloma cells.
    Blood. 1997 Jan 1;89(1):261-71 PMID: 8978300
  245. Cytogenetic findings in 200 patients with multiple myeloma.
    Cancer Genet Cytogenet. 1995 Jul 1;82(1):41-9 PMID: 7627933
  246. Apoptosis meets signal transduction: elimination of a BAD influence.
    Cell. 1996 Nov 15;87(4):589-92 PMID: 8929527
  247. Interleukin-6 in biology and medicine.
    Adv Immunol. 1993;54:1-78 PMID: 8379461
  248. Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes.
    Science. 1993 Jun 25;260(5116):1950-2 PMID: 8391166
  249. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines.
    Blood. 1996 Sep 15;88(6):2250-8 PMID: 8822946
  250. Chromosome studies in plasma cell leukemia and multiple myeloma in transformation.
    Genes Chromosomes Cancer. 1992 Jun;4(4):321-5 PMID: 1377939
  251. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis.
    Blood. 1995 Feb 1;85(3):757-64 PMID: 7530506
  252. Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies.
    Genes Chromosomes Cancer. 1993 Oct;8(2):80-7 PMID: 7504521
  253. Dysregulation of c-myc in multiple myeloma.
    Curr Top Microbiol Immunol. 1997;224:277-82 PMID: 9308252
  254. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.
    Nature. 1988 Mar 3;332(6159):83-5 PMID: 3258060
  255. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation.
    Blood. 1992 Nov 1;80(9):2326-35 PMID: 1421403
  256. Cytogenetic abnormalities in 13 patients with multiple myeloma.
    Cancer Genet Cytogenet. 1996 Feb;86(2):162-4 PMID: 8603346
  257. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity.
    J Immunol. 1995 Sep 1;155(5):2487-97 PMID: 7650379
  258. Oncogenes in multiple myeloma: point mutation of N-ras.
    Oncogene. 1990 Nov;5(11):1659-63 PMID: 2267133
  259. Messenger RNA levels of five genes located at chromosome 11q13 in B-cell tumors with chromosome translocation t(11;14)(q13;q32).
    Cancer Res. 1994 Jan 15;54(2):377-9 PMID: 8275473
  260. Aberrant translational control of the c-myc gene in multiple myeloma.
    Oncogene. 1996 Aug 1;13(3):505-13 PMID: 8760292
  261. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death.
    Curr Opin Genet Dev. 1994 Feb;4(1):102-8 PMID: 8193530
  262. Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells.
    Br J Haematol. 1991 Apr;77(4):523-8 PMID: 2025578
  263. A complex of Grb2 adaptor protein, Sos exchange factor, and a 36-kDa membrane-bound tyrosine phosphoprotein is implicated in ras activation in T cells.
    J Biol Chem. 1994 Mar 25;269(12):9019-23 PMID: 7510700
  264. Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma.
    Leukemia. 1997 Nov;11(11):1957-63 PMID: 9369432
  265. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.
    Cell. 1994 Jul 29;78(2):335-42 PMID: 7913883
  266. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
    Eur J Immunol. 1992 Aug;22(8):1989-93 PMID: 1639101
  267. Modulation of multidrug resistance in multiple myeloma.
    Baillieres Clin Haematol. 1995 Dec;8(4):831-44 PMID: 8845575
  268. Cyclin D and oncogenesis.
    Curr Opin Genet Dev. 1993 Feb;3(1):5-10 PMID: 8453274
  269. The CD19 signal transduction complex of B lymphocytes. Deletion of the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 and Leu 13.
    J Immunol. 1993 Sep 15;151(6):2915-27 PMID: 7690791
  270. The MAP kinase cascade is essential for diverse signal transduction pathways.
    Trends Biochem Sci. 1993 Apr;18(4):128-31 PMID: 8388132
  271. Biology and clinical aspects of the hematopoietic growth factors.
    Annu Rev Med. 1990;41:483-96 PMID: 2184746
  272. Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations.
    Carcinogenesis. 1992 Oct;13(10):1681-97 PMID: 1423827
  273. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy.
    Blood. 1993 Jan 1;81(1):128-35 PMID: 8417784
  274. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
    Br J Haematol. 1995 Mar;89(3):561-8 PMID: 7734355
  275. Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia.
    Leuk Lymphoma. 1996 Mar;21(1-2):25-30 PMID: 8907265
  276. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis.
    Blood. 1985 Aug;66(2):380-90 PMID: 3926026
  277. Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression.
    Blood. 1991 Oct 15;78(8):2070-4 PMID: 1912585
  278. Comparison of chromosome analysis and BCL-1 rearrangement in a series of patients with multiple myeloma.
    Br J Haematol. 1992 May;81(1):58-61 PMID: 1520625
  279. Multiple cytokines induce the tyrosine phosphorylation of Shc and its association with Grb2 in hemopoietic cells.
    J Biol Chem. 1993 Oct 15;268(29):21463-5 PMID: 7691810
  280. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry.
    Blood. 1990 Nov 1;76(9):1739-47 PMID: 2224123
  281. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
    Blood. 1996 Oct 1;88(7):2699-706 PMID: 8839865
  282. Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A.
    Acta Haematol. 1990;83(3):133-6 PMID: 2109452
  283. Cyclin D1 and p16INK4A are preferentially expressed in immature and mature myeloma cells, respectively.
    Br J Haematol. 1997 Oct;99(1):131-8 PMID: 9359513
  284. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
    Acta Haematol. 1997;97(4):191-5 PMID: 9158660
  285. IgH translocations in multiple myeloma: a nearly universal event that rarely involves c-myc.
    Curr Top Microbiol Immunol. 1997;224:283-7 PMID: 9308253
  286. Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma.
    Leukemia. 1993 Feb;7(2):241-5 PMID: 8426477
  287. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway.
    J Exp Med. 1994 Jan 1;179(1):167-75 PMID: 7505797
  288. Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates.
    Nature. 1992 Mar 5;356(6364):68-71 PMID: 1311423
  289. The oncoprotein phenotype of plasma cells from patients with multiple myeloma.
    Leuk Lymphoma. 1994 Dec;16(1-2):147-56 PMID: 7696921
  290. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma.
    Semin Hematol. 1995 Jan;32(1):4-19 PMID: 7878477
  291. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.
    Blood. 1993 Dec 15;82(12):3712-20 PMID: 8260708
  292. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor.
    Cytokine. 1992 Mar;4(2):96-100 PMID: 1633265
  293. Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways.
    J Biol Chem. 1996 Nov 22;271(47):30136-43 PMID: 8939963
  294. Multiple myeloma.
    N Engl J Med. 1997 Jun 5;336(23):1657-64 PMID: 9171069
  295. Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines.
    FEBS Lett. 1995 Dec 27;377(3):515-8 PMID: 8549788
  296. Molecular breakpoints of t(11;14)(q13;q32) in multiple myeloma.
    Cancer Genet Cytogenet. 1995 Aug;83(1):25-7 PMID: 7656199
  297. Interleukin-2-induced tyrosine phosphorylation of p52shc in T lymphocytes.
    J Biol Chem. 1993 Aug 25;268(24):17659-61 PMID: 7688728
  298. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation.
    Nature. 1993 May 6;363(6424):45-51 PMID: 8479536
  299. The role of interferon-alpha in the management of myelomatosis.
    Hematol Oncol Clin North Am. 1992 Apr;6(2):395-405 PMID: 1582981
  300. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
    Cancer Detect Prev. 1996;20(1):52-6 PMID: 8907203
  301. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.
    Nat Genet. 1995 Mar;9(3):321-8 PMID: 7773297
  302. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction.
    Cell. 1992 Jul 10;70(1):93-104 PMID: 1623525
  303. Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226.
    J Immunol. 1993 Aug 15;151(4):1811-20 PMID: 7688386
  304. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.
    Blood. 1995 May 1;85(9):2521-7 PMID: 7727780
  305. Vav is associated with signal transducing molecules gp130, Grb2 and Erk2, and is tyrosine phosphorylated in response to interleukin-6.
    FEBS Lett. 1997 Jan 20;401(2-3):133-7 PMID: 9013873
Article Info
Journal
Blood
Abbr.
Blood
ISSN
0006-4971
Published
1998-01-01
Pages
3-21
Language
English
Region
United States
NLM ID
7603509
PMCID
PMC3901996
Subset
IM
Grants
NCI NIH HHS · K01 CA074265-03 · United States
NCI NIH HHS · K01 CA074265-04 · United States
NCI NIH HHS · K01 CA074265-05 · United States
External Links
PubMed source PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2